Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




New Company To Promote and Commercialize bioMerieux Range in Japan

By HospiMedica staff writers
Posted on 22 Jan 2008
Sysmex Corp. More...
(Kobe, Japan; www.sysmex.com) and bioMerieux (Marcy l'Etoile, France; www.biomerieux.com) have signed an agreement to form a new company called Sysmex bioMerieux, Ltd. The company will promote and commercialize the entire bioMerieux product range in Japan.

bioMerieux has been operating in the Japanese clinical diagnostics and industrial testing market through bioMerieux Japan, Ltd., a fully owned subsidiary. The joint venture (JV) will manage the regulatory filing and marketing activities of bioMerieux product ranges in Japan. The sales and customer service activities will be contracted out from the JV to Sysmex.

Sysmex and bioMerieux have been developing their global partnership since July 2007, when bioMerieux became a global partner to distribute Sysmex's highly standardized and automated UF-1000i urine sediment analyzer to their extensive clinical microbiology customer base.

bioMérieux provides diagnostic products (reagents, instruments, software), which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are used for diagnosing infectious diseases and providing high medical value results for cardiovascular emergencies and cancer screening and monitoring. They are also used for detecting microorganisms in agri-food, pharmaceutical, and cosmetic products.

Sysmex performs clinical laboratory testing of blood, urine, and other specimens, providing instruments and reagents for clinical laboratory testing as well as laboratory information systems. The company, which specialized in hematology, has expanded to offer a comprehensive range of diagnostics products and solutions in the diagnostics field including coagulation, biochemistry, immunochemistry, urinalysis, and other disciplines.

The market volume of microbiology testing in Japan is estimated at approximately US$280 million per year and is regarded as a strategically important market, the second largest in size worldwide.


Related Links:
Sysmex Corporation
bioMerieux

Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
ESR Analyzer
TEST1 2.0
Gold Member
Hybrid Pipette
SWITCH
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.